Literature DB >> 15483020

Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88.

Urs E Studer1, Dieter Hauri, Silvia Hanselmann, Dominique Chollet, Hans-Jürg Leisinger, Thomas Gasser, Edgar Senn, Felix B Trinkler, Reto M Tscholl, George N Thalmann, Daniel Dietrich.   

Abstract

PURPOSE: To determine if immediate hormonal therapy is advantageous compared with deferred treatment in newly diagnosed asymptomatic prostate cancer patients who, for any reason, were not candidates for curative local treatment. PATIENTS AND METHODS: Between February 1988 and February 1992, 197 patients with a median age of 76 years (range, 56 to 86 years) were randomly assigned to receive either immediate or deferred orchiectomy on symptomatic progression. The two groups did not differ significantly in clinical or laboratory parameters; 67% had T3-4 tumors and 20% had lymph node metastases. Patient accrual was stopped prematurely because of a similar competing trial. Therefore, observation time was prolonged to achieve the desired number of events and statistical power.
RESULTS: Deferred orchiectomy was necessary in 58% of the patients. Median time to disease progression was 2.8 years less than for patients with immediate orchiectomy. However, overall pain-free time from random assignment to symptomatic progression after immediate or deferred orchiectomy, and performance status, were identical in both groups. Cancer-specific survival tended to be longer in the immediate group (P = .09) but there was no difference in overall survival between the two groups (P = .96). The median hemoglobin value decreased significantly after immediate orchiectomy (P < .001).
CONCLUSION: For elderly, asymptomatic patients not undergoing curative local treatment, we were unable to show any major advantage of immediate compared with deferred hormonal treatment regarding quality of life or overall survival in our limited number of patients. Disabling complications were prevented in the deferred-treatment arm by careful follow-up; 42% of these patients never required any tumor-specific treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15483020     DOI: 10.1200/JCO.2004.11.514

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

1.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 2.  Androgen suppression strategies for prostate cancer: is there an ideal approach?

Authors:  Mohamed Ismail; Matthew Ferroni; Leonard G Gomella
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 3.  Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Authors:  Jarad M Martin; Stephane Supiot; Dominik R Berthold
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

4.  Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer.

Authors:  Yong-Fang Kuo; James E Montie; Vahakn B Shahinian
Journal:  Med Care       Date:  2012-05       Impact factor: 2.983

Review 5.  Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Authors:  Roisin M Connolly; Michael A Carducci; Emmanuel S Antonarakis
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

6.  Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.

Authors:  Kathryn Bylow; William Dale; Karen Mustian; Walter M Stadler; Miriam Rodin; William Hall; Mark Lachs; Supriya G Mohile
Journal:  Urology       Date:  2008-06-17       Impact factor: 2.649

Review 7.  Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

8.  Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?

Authors:  L Klotz; P Toren
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

9.  Early and delayed castrations confer a similar survival advantage in TRAMP mice.

Authors:  Zai-Xian Zhang; Qing-Quan Xu; Xiao-Bo Huang; Ji-Chuan Zhu; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2009-04-27       Impact factor: 3.285

10.  Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Authors:  Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao
Journal:  JAMA       Date:  2008-07-09       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.